BioArctic

BioArctic Enterprise Value

The Enterprise Value (EV) of BioArctic (BIOA B.ST) as of Sep 29, 2026 is 25.23 B SEK. In the previous year, Enterprise Value (EV) was 26.65 B SEK — a change of -5.34% (lower).

Enterprise Value

25.23 BSEK

YoY

-5.34%

Last updated:

Enterprise Value (EV) of BioArctic is 2026 25.23 B SEK. Enterprise Value (EV) of BioArctic was 2025 26.65 B SEK. It decreases by -5.34% lower compared to the previous year.

The BioArctic Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
26.25 B SEK
Jan 1, 2019
26.29 B SEK
Jan 1, 2020
26.39 B SEK
Jan 1, 2021
26.54 B SEK
Jan 1, 2022
26.58 B SEK
Jan 1, 2023
26.27 B SEK
Jan 1, 2024
26.65 B SEK
Jan 1, 2025
25.23 B SEK
The BioArctic Enterprise Value history
YEAREnterprise ValueYoY
25.23 BSEK-5.34%
26.65 BSEK+1.45%
26.27 BSEK-1.17%
26.58 BSEK+0.14%
26.54 BSEK+0.56%
26.39 BSEK+0.40%
26.29 BSEK+0.16%
26.25 BSEK+1.77%
25.79 BSEK-3.34%
26.68 BSEK-2.12%
27.26 BSEK—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Enterprise Value (EV) of BioArctic is 25.23 B SEK in 2026.

Enterprise Value (EV) of BioArctic changed from 26.65 B SEK to 25.23 B SEK, representing a -5.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) BioArctic since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s SEK, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' SEK varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s BioArctic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — BioArctic

All Key Metrics — BioArctic